The 2026 tau imaging news means adults with thinking or memory problems have a second FDA-cleared tau PET option, Tauklarify, during an Alzheimer's evaluation. Tau PET is a brain scan that maps tau tangles, a core Alzheimer's marker.
For primary-care workups, this adds a confirmatory step after initial blood testing and gives patients clear questions about referral, fit, and cost. The change does not replace a clinical exam, history, or first-line blood work. It gives the clinician one more tool when scan results would shape next steps.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed in 2026?
- How could it fit a primary-care workup?
- What limits should patients understand?
- Which questions should you bring to a clinician?
What changed in 2026?
Lantheus announced FDA approval of Tauklarify, florquinitau F 18 and formerly MK-6240, on Aug. 14, 2026 for brain PET in cognitively impaired adults being evaluated for Alzheimer's to identify tau tangle pathology, according to Lantheus in the FDA approval notice. The use is narrow: find tau pathology as part of an Alzheimer's workup. Tauklarify is the second FDA-cleared tau PET tracer after flortaucipir, Tauvid from 2020, according to ALZFORUM in ALZFORUM's diagnostic suite summary.
ALZFORUM places it alongside three amyloid PET tracers, three spinal-fluid tests, and four blood tests. Early-detection research adds context. In the 682-person HEAD study at eight U.S. and Canadian sites, MK-6240 found medial-temporal tau in 15% of cognitively unimpaired amyloid-positive people versus 6% with flortaucipir, according to the University of Pittsburgh. The pattern suggests detection before symptoms in at-risk adults.
How could it fit a primary-care workup?
The 2024 Alzheimer's Association revised criteria define Alzheimer's by biology, using core biomarkers rather than symptoms alone. In practice, many clinics favor blood-first triage, then confirmatory PET or spinal-fluid testing when needed. Updated appropriate-use criteria from SNMMI and the Alzheimer's Association, issued in Jan. 2025, recommend amyloid or tau PET when the result will change care, according to Applied Radiology and SNMMI.
That includes sorting out competing causes and checking eligibility or response for anti-amyloid therapy. For patients, the effect is practical. A primary-care clinician may still start with history, cognitive testing, labs, and a blood biomarker test. Tau PET enters later, after referral, when tau status would alter diagnosis, referrals, treatment choices, or planning.
What limits should patients understand?
The label limits use to Alzheimer's evaluation. Safety and effectiveness are not established for other tau conditions such as progressive supranuclear palsy or frontotemporal dementia, according to the Lantheus prescribing information. Accuracy also has a gap. Validation compared mainly amyloid-negative unimpaired people against amyloid-positive impaired patients, so accuracy is lower in middle stages, according to Pharmacy Times in Pharmacy Times' summary of the label limits.
A negative scan does not rule out tau pathology, and a positive scan alone does not prove Alzheimer's. Safety events were uncommon in testing. Headache occurred in 0.7% and nausea in 0.2% among 1,734 participants, according to Pharmacy Times. Instructions call for radiation precautions, hydration and voiding, avoiding CYP1A2 inducers and smoking for 7 days, and pausing breastfeeding for 4 hours.
Which questions should you bring to a clinician?
Bring a short list and ask which answers apply to your case. The goal is to learn whether tau PET would change your care, where you would go, and what you would pay.
Coverage remains a key question. CMS left amyloid PET coverage to local contractors, with no national tau-PET price, according to the CMS manual. Ask the clinic to check referral rules, prior authorization, and self-pay cost before scheduling.
- Would a blood test come first, and what result would prompt PET or spinal-fluid confirmation?
- Would tau PET change my diagnosis, treatment eligibility, referral, or care plan?
- Am I in the labeled group: cognitively impaired and being evaluated for Alzheimer's?
- Where would the scan occur, how do I prepare, and what safety steps apply to me?
- What will my plan cover, is coverage local, and what is my likely out-of-pocket cost?
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions Primary Care Patients Can Bring to a Clinician
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions Primary Care Patients Can Bring to a Clinician
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Primary Care Patients Can Bring to a Clinician
